{"text": ["UK", "cost", "watchdog", "recommends", "Novartis'", "blindness", "therapy", "Luxturna"], "created_at": "2019-09-03 23:01:01"}
{"text": ["Global", "Blood", "Focuses", "on", "Lead", "Candidate", "Amid", "Competition"], "created_at": "2019-09-03 15:09:59"}
{"text": ["Global", "Blood", "Focuses", "on", "Lead", "Candidate", "Amid", "Competition"], "created_at": "2019-09-03 15:09:59"}
{"text": ["5", "Cancer-Fighting", "Stocks", "to", "Add", "to", "Your", "Portfolio"], "created_at": "2019-09-03 13:30:48"}
{"text": ["5", "Cancer-Fighting", "Stocks", "to", "Add", "to", "Your", "Portfolio"], "created_at": "2019-09-03 13:30:48"}
{"text": ["Vertex", "snaps", "up", "Cambridge", "diabetes", "startup", "Semma", "for", "$950M"], "created_at": "2019-09-03 13:06:47"}
{"text": ["Global", "Blood", "Focuses", "on", "Lead", "Candidate", "Amid", "Competition"], "created_at": "2019-09-03 12:45:12"}
{"text": ["5", "Cancer-Fighting", "Stocks", "to", "Add", "to", "Your", "Portfolio"], "created_at": "2019-09-03 11:02:11"}
{"text": ["UPDATE", "1-Novartis,", "Lonza", "deepen", "biosimilars", "push", "with", "MS,", "arthritis", "drug", "deals"], "created_at": "2019-09-03 08:42:51"}
{"text": ["Novartis's", "Sandoz", "licenses", "proposed", "multiple", "sclerosis", "biosimilar"], "created_at": "2019-09-03 05:52:06"}
